As of September 30, 2024, Aethlon Medical (AEMD) had a cash balance of approximately $6.9M. “During Q2 and subsequent period, we continued advancing our oncology trials, earlier this week announcing enrollment of the first patient at Royal Adelaide Hospital, and now updating this news to report enrollment of a second patient. This represents a critical milestone for the safety, feasibility and dose-finding trials of the Hemopurifier in patients with solid tumors who have failed treatment with anti-PD-1 antibodies,” stated CEO and CFO James Frakes. “We now have two sites open for patient enrollment in Australia, have received ethics committee approval from a site in India, and we expect to continue to enroll subjects in our Hemopurifier cancer trial. As previously announced, we believe these studies will help inform future oncology efficacy trials. Additionally, we have made strategic cost-cutting measures to optimize company resources, in order to focus on the high-impact oncology trials in both Australia and India.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEMD:
- Aethlon Medical enrolls first patient in Hemopurifier cancer trial in Australia
- AEMD Earnings this Week: How Will it Perform?
- Aethlon Medical Appoints James B. Frakes as CEO
- Aethlon Medical Shareholders Approve Key Decisions at Annual Meeting
- Aethlon Medical Hemopurifier cancer trial in India approved by ethics committee